Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Aligos Therapeutics, Inc. shareholders approved Ratification of the selection by the audit committee of the board of directors of the Company of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. at the 2023-07-20 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-07-20
Exact text from the filing
Proposal 2 . The ratification of the selection by the audit committee of the board of directors of the Company of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. The results of the vote were as follows: Votes For Votes Against Abstentions 34,670,204 11,096 918
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Aligos Therapeutics, Inc. shareholders approved Election of three Class III directors to hold office until the 2026 annual meeting of stockholders or until their respective successor is elected. at the 2023-07-20 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-07-20
Exact text from the filing
Proposal 1 . The election of three Class III directors to hold office until the 2026 annual meeting of stockholders or until their respective successor is elected. The results of the vote were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Jack B. Nielsen 20,201,692 4,766,666 9,713,860 Bridget Martell, M.A., M.D. 24,022,757 945,601 9,713,860 Carole Nuechterlein, J.D. 21,653,372 3,314,986 9,713,860
View on SEC.gov